Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bladder Cancer-Pipeline Review, H1 2015

Bladder Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Bladder Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bladder Cancer-Pipeline Review, H1 2015', provides an overview of the Bladder Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Bladder Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bladder Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 11

Introduction 12

Global Markets Direct Report Coverage 12

Bladder Cancer Overview 13

Therapeutics Development 14

Pipeline Products for Bladder Cancer-Overview 14

Pipeline Products for Bladder Cancer-Comparative Analysis 15

Bladder Cancer-Therapeutics under Development by Companies 16

Bladder Cancer-Therapeutics under Investigation by Universities/Institutes 24

Bladder Cancer-Pipeline Products Glance 25

Late Stage Products 25

Clinical Stage Products 26

Early Stage Products 27

Bladder Cancer-Products under Development by Companies 28

Bladder Cancer-Products under Investigation by Universities/Institutes 36

Bladder Cancer-Companies Involved in Therapeutics Development 37

Advaxis, Inc. 37

Alligator Bioscience AB 38

Alnylam Pharmaceuticals, Inc. 39

Altor BioScience Corporation 40

Amgen Inc. 41

AndroScience Corporation 42

APIM Therapeutics AS 43

Arno Therapeutics, Inc. 44

Ascenta Therapeutics, Inc. 45

Astellas Pharma Inc. 46

AstraZeneca Plc 47

AuraSense Therapeutics, LLC 48

AVEO Pharmaceuticals, Inc. 49

AvidBiotics Corp. 50

Bavarian Nordic A/S 51

Bayer AG 52

BioCancell Ltd 53

Bioncotech Therapeutics S.L. 54

Biotest AG 55

cCAM Biotherapeutics Ltd. 56

Celgene Corporation 57

Cold Genesys, Inc. 58

Daiichi Sankyo Company, Limited 59

Dompe Farmaceutici S.p.A. 60

DormaTarg, Inc. 61

Eisai Co., Ltd. 62

Eli Lilly and Company 63

EntreChem, S.L. 64

Esperance Pharmaceuticals, Inc. 65

Evotec AG 66

F. Hoffmann-La Roche Ltd. 67

Gene Signal International SA 68

Genmab A/S 69

GlaxoSmithKline Plc 70

Heat Biologics, Inc. 71

Hutchison MediPharma Limited 72

Idera Pharmaceuticals, Inc. 73

Immunomedics, Inc. 74

Immupharma Plc 75

ImmuRx, Inc. 76

Incyte Corporation 77

Lipella Pharmaceuticals, Inc. 78

MacroGenics, Inc. 79

Marina Biotech, Inc. 80

MedImmune, LLC 81

Merck & Co., Inc. 82

Millennium Pharmaceuticals, Inc. 83

Mirati Therapeutics Inc. 84

NuCana BioMed Limited 85

Omeros Corporation 86

Oncogenex Pharmaceuticals, Inc. 87

Oncolytics Biotech Inc. 88

Oncopeptides AB 89

Ono Pharmaceutical Co., Ltd. 90

Optimum Therapeutics, LLC 91

Panacela Labs, Inc. 92

Pfizer Inc. 93

Pharma Mar, S.A. 94

Polaris Pharmaceuticals, Inc. 95

PsiOxus Therapeutics Limited 96

Qu Biologics Inc. 97

Quest PharmaTech Inc. 98

Samyang Holdings Corporation 99

Sanofi 100

SentoClone International AB 101

Serometrix, LLC 102

Shionogi & Co., Ltd. 103

Spectrum Pharmaceuticals, Inc. 104

Stemline Therapeutics, Inc. 105

Synta Pharmaceuticals Corp. 106

TARIS BioMedical, Inc. 107

Telesta Therapeutics Inc. 108

Telormedix SA 109

Theravectys S.A. 110

TheRyte Limited 111

Tolero Pharmaceuticals, Inc. 112

Transgene SA 113

Vakzine Projekt Management GmbH 114

Viralytics Ltd. 115

Viventia Biotechnologies Inc. 116

Bladder Cancer-Therapeutics Assessment 117

Assessment by Monotherapy Products 117

Assessment by Combination Products 118

Assessment by Target 119

Assessment by Mechanism of Action 124

Assessment by Route of Administration 128

Assessment by Molecule Type 130

Drug Profiles 132

ACP-196-Drug Profile 132

ADC-1013-Drug Profile 134

afuresertib hydrochloride + trametinib dimethyl sulfoxide-Drug Profile 136

aganirsen-Drug Profile 137

ALT-801-Drug Profile 139

ALT-803-Drug Profile 141

Antibody to Inhibit TYRO-3 for Bladder Carcinoma-Drug Profile 143

Antisense Oligonucleotides for Bladder Cancer-Drug Profile 144

apatorsen-Drug Profile 145

apaziquone-Drug Profile 147

APL-1202-Drug Profile 149

APTA-012-Drug Profile 150

AR-42-Drug Profile 151

ASC-JM.Z1-Drug Profile 153

ASG-15ME-Drug Profile 154

AST-008-Drug Profile 155

AT-406-Drug Profile 156

atezolizumab-Drug Profile 159

ATX-101-Drug Profile 162

AV-203-Drug Profile 163

AZD-4547-Drug Profile 164

AZD-5312-Drug Profile 166

B-701-Drug Profile 167

BAY-1163877-Drug Profile 168

BC-819-Drug Profile 169

Biologic for Superficial Bladder Cancer-Drug Profile 172

BO-110-Drug Profile 173

BV-2711-Drug Profile 174

CG-0070-Drug Profile 175

CM-24-Drug Profile 177

CV-301-Drug Profile 178

CVA-21-Drug Profile 180

DAB-389EGF-Drug Profile 184

Dendritic Cell Therapy to Target HER-2 for Oncology-Drug Profile 185

Drug for Bladder Cancer-Drug Profile 186

Drug for NMIBC-Drug Profile 187

Drugs to Inhibit FGFR3 for Bladder Cancer-Drug Profile 188

Drugs to Inhibit TYRO-3 for Bladder Carcinoma-Drug Profile 189

dsP21-322-2'F-Drug Profile 190

DT-310-Drug Profile 191

DT-320-Drug Profile 192

DT-330-Drug Profile 193

durvalumab + tremelimumab-Drug Profile 194

EC-7072-Drug Profile 196

enadenotucirev-Drug Profile 197

enoblituzumab-Drug Profile 199

EP-400-Drug Profile 200

epacadostat-Drug Profile 201

eribulin mesylate-Drug Profile 203

GSK-2849330-Drug Profile 207

HMPL-453-Drug Profile 208

HuMax-TF-ADC-Drug Profile 209

ICT-2700-Drug Profile 210

imiquimod-Drug Profile 211

IMO-2055-Drug Profile 212

indatuximab ravtansine-Drug Profile 214

IPP-204106-Drug Profile 216

Lm-LLO-ISG15-Drug Profile 218

lurbinectedin-Drug Profile 220

MDNA-55-Drug Profile 223

MDR-09521-Drug Profile 224

Melflufen-Drug Profile 225

mitomycin-Drug Profile 227

MMD-37K-Drug Profile 229

mocetinostat-Drug Profile 230

Monoclonal Antibodies to Inhibit VISTA for Bladder Cancer-Drug Profile 233

Monoclonal Antibody for Bladder Cancer, Lymphoma and Myeloma-Drug Profile 234

Monoclonal Antibody to Inhibit EGFR for Superficial Bladder Cancer-Drug Profile 235

MVAME-03-Drug Profile 236

MVXONCO-1-Drug Profile 237

nivolumab-Drug Profile 238

NUC-1031-Drug Profile 244

OGX-225-Drug Profile 246

oportuzumab monatox-Drug Profile 247

paclitaxel-Drug Profile 249

paclitaxel albumin bound-Drug Profile 251

panitumumab-Drug Profile 255

patritumab-Drug Profile 258

pegargiminase-Drug Profile 260

pelareorep-Drug Profile 263

pembrolizumab-Drug Profile 268

QBECP-SSI-Drug Profile 275

rAd-IFN-Drug Profile 276

ramucirumab-Drug Profile 278

recMAGE-A3 + AS15-Drug Profile 284

Recombinant BCG-Pertussis Vaccine-Drug Profile 286

Recombinant Protein for Oncology and Infectious Disease-Drug Profile 287

RNAi Oligonucleotide to Inhibit TYRO-3 for Bladder Carcinoma-Drug Profile 288

RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer-Drug Profile 289

S-588410-Drug Profile 291

sacituzumab govitecan-Drug Profile 292

sapanisertib-Drug Profile 293

SAR-408701-Drug Profile 295

Sentoclone-Drug Profile 296

sirolimus albumin-bound-Drug Profile 297

SL-052-Drug Profile 299

SL-601-Drug Profile 301

Small molecule for Bladder Cancer-Drug Profile 302

Small Molecule to Antagonize GPR87 for Cancer-Drug Profile 303

Small Molecule to Inhibit TDO-2 for Cancer-Drug Profile 304

Small Molecule to Inhibit TYRO3 for Bladder Carcinoma-Drug Profile 306

Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer-Drug Profile 307

Small Molecules to Antagonize CXCR1/2 for Bladder and Prostate Cancer-Drug Profile 308

Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis-Drug Profile 309

STA-128666-Drug Profile 310

suramin hexasodium-Drug Profile 312

SX-MTR1-Drug Profile 314

TD-210-Drug Profile 315

TF-011 Monomethyl Auristatin E-Drug Profile 316

TG-6002-Drug Profile 318

THR-53-Drug Profile 319

TMX-202-Drug Profile 320

TP-3654-Drug Profile 321

Urocidin-Drug Profile 322

Vaccine for Urogenital Cancers-Drug Profile 324

Vaccine to Target NY-ESO-1 for Oncology-Drug Profile 325

vemurafenib-Drug Profile 326

vesigenurtucel-L-Drug Profile 330

VPM-1002-Drug Profile 331

Bladder Cancer-Recent Pipeline Updates 333

Bladder Cancer-Dormant Projects 440

Bladder Cancer-Discontinued Products 446

Bladder Cancer-Product Development Milestones 447

Featured News & Press Releases 447

Appendix 455

Methodology 455

Coverage 455

Secondary Research 455

Primary Research 455

Expert Panel Validation 455

Contact Us 455

Disclaimer 456

List of Tables

Number of Products under Development for Bladder Cancer, H1 2015 22

Number of Products under Development for Bladder Cancer-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 25

Number of Products under Development by Companies, H1 2015 (Contd..1) 26

Number of Products under Development by Companies, H1 2015 (Contd..2) 27

Number of Products under Development by Companies, H1 2015 (Contd..3) 28

Number of Products under Development by Companies, H1 2015 (Contd..4) 29

Number of Products under Development by Companies, H1 2015 (Contd..5) 30

Number of Products under Development by Companies, H1 2015 (Contd..6) 31

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Late Stage Development, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Development, H1 2015 35

Products under Development by Companies, H1 2015 36

Products under Development by Companies, H1 2015 (Contd..1) 37

Products under Development by Companies, H1 2015 (Contd..2) 38

Products under Development by Companies, H1 2015 (Contd..3) 39

Products under Development by Companies, H1 2015 (Contd..4) 40

Products under Development by Companies, H1 2015 (Contd..5) 41

Products under Development by Companies, H1 2015 (Contd..6) 42

Products under Development by Companies, H1 2015 (Contd..7) 43

Products under Investigation by Universities/Institutes, H1 2015 44

Bladder Cancer-Pipeline by Advaxis, Inc., H1 2015 45

Bladder Cancer-Pipeline by Alligator Bioscience AB, H1 2015 46

Bladder Cancer-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 47

Bladder Cancer-Pipeline by Altor BioScience Corporation, H1 2015 48

Bladder Cancer-Pipeline by Amgen Inc., H1 2015 49

Bladder Cancer-Pipeline by AndroScience Corporation, H1 2015 50

Bladder Cancer-Pipeline by APIM Therapeutics AS, H1 2015 51

Bladder Cancer-Pipeline by Arno Therapeutics, Inc., H1 2015 52

Bladder Cancer-Pipeline by Ascenta Therapeutics, Inc., H1 2015 53

Bladder Cancer-Pipeline by Astellas Pharma Inc., H1 2015 54

Bladder Cancer-Pipeline by AstraZeneca Plc, H1 2015 55

Bladder Cancer-Pipeline by AuraSense Therapeutics, LLC, H1 2015 56

Bladder Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 57

Bladder Cancer-Pipeline by AvidBiotics Corp., H1 2015 58

Bladder Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 59

Bladder Cancer-Pipeline by Bayer AG, H1 2015 60

Bladder Cancer-Pipeline by BioCancell Ltd, H1 2015 61

Bladder Cancer-Pipeline by Bioncotech Therapeutics S.L., H1 2015 62

Bladder Cancer-Pipeline by Biotest AG, H1 2015 63

Bladder Cancer-Pipeline by cCAM Biotherapeutics Ltd., H1 2015 64

Bladder Cancer-Pipeline by Celgene Corporation, H1 2015 65

Bladder Cancer-Pipeline by Cold Genesys, Inc., H1 2015 66

Bladder Cancer-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 67

Bladder Cancer-Pipeline by Dompe Farmaceutici S.p.A., H1 2015 68

Bladder Cancer-Pipeline by DormaTarg, Inc., H1 2015 69

Bladder Cancer-Pipeline by Eisai Co., Ltd., H1 2015 70

Bladder Cancer-Pipeline by Eli Lilly and Company, H1 2015 71

Bladder Cancer-Pipeline by EntreChem, S.L., H1 2015 72

Bladder Cancer-Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 73

Bladder Cancer-Pipeline by Evotec AG, H1 2015 74

Bladder Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 75

Bladder Cancer-Pipeline by Gene Signal International SA, H1 2015 76

Bladder Cancer-Pipeline by Genmab A/S, H1 2015 77

Bladder Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 78

Bladder Cancer-Pipeline by Heat Biologics, Inc., H1 2015 79

Bladder Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 80

Bladder Cancer-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 81

Bladder Cancer-Pipeline by Immunomedics, Inc., H1 2015 82

Bladder Cancer-Pipeline by Immupharma Plc, H1 2015 83

Bladder Cancer-Pipeline by ImmuRx, Inc., H1 2015 84

Bladder Cancer-Pipeline by Incyte Corporation, H1 2015 85

Bladder Cancer-Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 86

Bladder Cancer-Pipeline by MacroGenics, Inc., H1 2015 87

Bladder Cancer-Pipeline by Marina Biotech, Inc., H1 2015 88

Bladder Cancer-Pipeline by MedImmune, LLC, H1 2015 89

Bladder Cancer-Pipeline by Merck & Co., Inc., H1 2015 90

Bladder Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 91

Bladder Cancer-Pipeline by Mirati Therapeutics Inc., H1 2015 92

Bladder Cancer-Pipeline by NuCana BioMed Limited, H1 2015 93

Bladder Cancer-Pipeline by Omeros Corporation, H1 2015 94

Bladder Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 95

Bladder Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 96

Bladder Cancer-Pipeline by Oncopeptides AB, H1 2015 97

Bladder Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 98

Bladder Cancer-Pipeline by Optimum Therapeutics, LLC, H1 2015 99

Bladder Cancer-Pipeline by Panacela Labs, Inc., H1 2015 100

Bladder Cancer-Pipeline by Pfizer Inc., H1 2015 101

Bladder Cancer-Pipeline by Pharma Mar, S.A., H1 2015 102

Bladder Cancer-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 103

Bladder Cancer-Pipeline by PsiOxus Therapeutics Limited, H1 2015 104

Bladder Cancer-Pipeline by Qu Biologics Inc., H1 2015 105

Bladder Cancer-Pipeline by Quest PharmaTech Inc., H1 2015 106

Bladder Cancer-Pipeline by Samyang Holdings Corporation, H1 2015 107

Bladder Cancer-Pipeline by Sanofi, H1 2015 108

Bladder Cancer-Pipeline by SentoClone International AB, H1 2015 109

Bladder Cancer-Pipeline by Serometrix, LLC, H1 2015 110

Bladder Cancer-Pipeline by Shionogi & Co., Ltd., H1 2015 111

Bladder Cancer-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 112

Bladder Cancer-Pipeline by Stemline Therapeutics, Inc., H1 2015 113

Bladder Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 114

Bladder Cancer-Pipeline by TARIS BioMedical, Inc., H1 2015 115

Bladder Cancer-Pipeline by Telesta Therapeutics Inc., H1 2015 116

Bladder Cancer-Pipeline by Telormedix SA, H1 2015 117

Bladder Cancer-Pipeline by Theravectys S.A., H1 2015 118

Bladder Cancer-Pipeline by TheRyte Limited, H1 2015 119

Bladder Cancer-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 120

Bladder Cancer-Pipeline by Transgene SA, H1 2015 121

Bladder Cancer-Pipeline by Vakzine Projekt Management GmbH, H1 2015 122

Bladder Cancer-Pipeline by Viralytics Ltd., H1 2015 123

Bladder Cancer-Pipeline by Viventia Biotechnologies Inc., H1 2015 124

Assessment by Monotherapy Products, H1 2015 125

Assessment by Combination Products, H1 2015 126

Number of Products by Stage and Target, H1 2015 128

Number of Products by Stage and Mechanism of Action, H1 2015 133

Number of Products by Stage and Route of Administration, H1 2015 137

Number of Products by Stage and Molecule Type, H1 2015 139

Bladder Cancer Therapeutics-Recent Pipeline Updates, H1 2015 341

Bladder Cancer-Dormant Projects, H1 2015 448

Bladder Cancer-Dormant Projects (Contd..1), H1 2015 449

Bladder Cancer-Dormant Projects (Contd..2), H1 2015 450

Bladder Cancer-Dormant Projects (Contd..3), H1 2015 451

Bladder Cancer-Dormant Projects (Contd..4), H1 2015 452

Bladder Cancer-Dormant Projects (Contd..5), H1 2015 453

Bladder Cancer-Discontinued Products, H1 2015 454

List of Figures

Number of Products under Development for Bladder Cancer, H1 2015 22

Number of Products under Development for Bladder Cancer-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 24

Number of Products under Investigation by Universities/Institutes, H1 2015 32

Comparative Analysis by Clinical Stage Development, H1 2015 34

Comparative Analysis by Early Stage Products, H1 2015 35

Assessment by Monotherapy Products, H1 2015 125

Assessment by Combination Products, H1 2015 126

Number of Products by Top 10 Targets, H1 2015 127

Number of Products by Stage and Top 10 Targets, H1 2015 127

Number of Products by Top 10 Mechanism of Actions, H1 2015 132

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 132

Number of Products by Top 10 Routes of Administration, H1 2015 136

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 136

Number of Products by Top 10 Molecule Types, H1 2015 138

Number of Products by Stage and Top 10 Molecule Types, H1 2015 138

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advaxis, Inc.

Alligator Bioscience AB

Alnylam Pharmaceuticals, Inc.

Altor BioScience Corporation

Amgen Inc.

AndroScience Corporation

APIM Therapeutics AS

Arno Therapeutics, Inc.

Ascenta Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

AuraSense Therapeutics, LLC

AVEO Pharmaceuticals, Inc.

AvidBiotics Corp.

Bavarian Nordic A/S

Bayer AG

BioCancell Ltd

Bioncotech Therapeutics S.L.

Biotest AG

cCAM Biotherapeutics Ltd.

Celgene Corporation

Cold Genesys, Inc.

Daiichi Sankyo Company, Limited

Dompe Farmaceutici S.p.A.

DormaTarg, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

Esperance Pharmaceuticals, Inc.

Evotec AG

F. Hoffmann-La Roche Ltd.

Gene Signal International SA

Genmab A/S

GlaxoSmithKline Plc

Heat Biologics, Inc.

Hutchison MediPharma Limited

Idera Pharmaceuticals, Inc.

Immunomedics, Inc.

Immupharma Plc

ImmuRx, Inc.

Incyte Corporation

Lipella Pharmaceuticals, Inc.

MacroGenics, Inc.

Marina Biotech, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

NuCana BioMed Limited

Omeros Corporation

Oncogenex Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

Oncopeptides AB

Ono Pharmaceutical Co., Ltd.

Optimum Therapeutics, LLC

Panacela Labs, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

PsiOxus Therapeutics Limited

Qu Biologics Inc.

Quest PharmaTech Inc.

Samyang Holdings Corporation

Sanofi

SentoClone International AB

Serometrix, LLC

Shionogi & Co., Ltd.

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Synta Pharmaceuticals Corp.

TARIS BioMedical, Inc.

Telesta Therapeutics Inc.

Telormedix SA

Theravectys S.A.

TheRyte Limited

Tolero Pharmaceuticals, Inc.

Transgene SA

Vakzine Projekt Management GmbH

Viralytics Ltd.

Viventia Biotechnologies Inc.

Bladder Cancer Therapeutic Products under Development, Key Players in Bladder Cancer Therapeutics, Bladder Cancer Pipeline Overview, Bladder Cancer Pipeline, Bladder Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com